Armstrong Advisory Group’s Ligand Pharmaceuticals LGND Stock Holding History

Armstrong Advisory Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$625	Buy	+2	New	+$591	﹤0.01%	1001

Other funds holding LGND

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Armstrong Advisory Group's LGND Position: Q3 2026 in Review

Armstrong Advisory Group opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2026: 2 shares worth $625. The stake represents ﹤0.01% of the portfolio and ranks #1001 among its holdings.

348 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Armstrong Advisory Group held 2 shares of Ligand Pharmaceuticals worth $625 as of Q3 2026.
Ligand Pharmaceuticals was a new Armstrong Advisory Group position in Q3 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #1001 holding.
348 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.